Mankind Pharma posts 30% profit rise on chronic therapies demand
Indian drugmaker bucks sector weakness as domestic revival offsets US headwinds faced by peers
Author
Markets reporter
Tom Harland reports on pharma and biotech earnings, guidance, share moves and IPOs for PharmaWire.
Indian drugmaker bucks sector weakness as domestic revival offsets US headwinds faced by peers
Rocket Pharmaceuticals, the US gene therapy specialist, has bought itself an additional two years of operational runway through the $180mn sale of a regulatory voucher, easing pressure on a balance sheet that had been narrowing as the New…
Jazz Pharmaceuticals, the Dublin-headquartered drugmaker, has delivered a markedly stronger first-quarter performance than analysts had anticipated, capping a twelve-month period in which the stock has more than doubled — and prompting a…
Brano Therapeutics raised $6.8 million in seed financing to support the development of new therapies targeting heart failure, including Heart Failure with preserved Ejection Fraction (HFpEF), an area where treatment options remain limited.
Zealand Pharma shares climbed after the company reported positive clinical progress across its obesity pipeline and strengthened its financial outlook with expected milestone payments from partner Roche.
Neimeth International Pharmaceuticals, one of Nigeria's longest-established drugmakers, posted strong revenue growth in the first quarter of 2026, continuing a turnaround that has lifted the Lagos-listed group out of three years of losses…
Analysts have cut their earnings forecasts for Fine Foods & Pharmaceuticals N.T.M., the Italian contract development and manufacturing group, after a first-quarter result that came in broadly in line with expectations but failed to prevent…
For a company that not so long ago was the most valuable in Europe, Novo Nordisk has spent the past year looking unusually mortal. Its share price has shed 30% over twelve months. Its forecasts have been cut. Its American arch-rival, Eli…
Faron Pharmaceuticals, the Finnish clinical-stage immunotherapy group, has terminated its liquidity provision agreement with Lago Kapital, citing improved natural trading activity in its shares — a notable signal of the dual-listed…
Jazz Pharmaceuticals will report first-quarter results after the US market closes on Tuesday, with investors weighing the Dublin-headquartered drugmaker's recent commercial trajectory against the buoyant tone struck by larger…
Alnylam Pharmaceuticals, the US biotech that has long been the standard-bearer for the RNA interference therapeutic class, has swung to a quarterly profit on the back of a surge in product sales, marking a watershed for a company whose…
Shares in Ionis Pharmaceuticals have surged more than 150 per cent over the past year, prompting investors to reassess whether further upside remains or if much of the growth story is already priced in.
Heights Capital Management, the San Francisco-based investment firm, has disclosed a 25.44 per cent stake in Faron Pharmaceuticals, the Finnish biotech, cementing its position as a dominant financial backer of the loss-making drug…
Belpointe Asset Management has opened a new position in Regeneron Pharmaceuticals worth approximately $1.74mn, according to the latest quarterly regulatory filing from the Reno-based investment manager, in the latest sign of renewed…
Fremont-based protein biomarker company prices at top of range amid demand running at more than ten times available shares
Telix Pharmaceuticals has raised $600mn through an upsized convertible bond offering, reflecting strong investor demand for the group’s refinancing.
Neil Kumar, chief executive of BridgeBio Pharma, has sold nearly $6mn worth of shares in the company, according to a regulatory filing.